NCT07104721View on ClinicalTrials.gov

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

August 4, 2026

Study Completion Date

December 30, 2028

Conditions
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Systemic Sclerosis (SSc)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid Syndrome (APS)
Interventions
DRUG

YTS109 cell

Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3×10⁶ STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY